Drug prices shift as COVID-19 begins making its mark on the supply chain

For the past 20 months, in the pre-COVID-19 era, we’ve released a monthly report called “What’s Happening To Generic Drug Prices,” where we track month-by-month price changes from the CMS National Average Drug Acquisition Cost (NADAC) survey of community pharmacy invoice acquisition costs for prescription drugs. This month, we still are providing that update, but in digging through the latest round of drug pricing data from CMS, we spotted some very interesting drug pricing movement on generic drugs, and one massive increase on a drug that was recently being tested for emergency use for treatment of COVID-19 patients. Check out our latest drug pricing report for important updates on the latest drug price changes, plus an updated NADAC Packed Bubble Chart and Abnormal Drug Price Increase Tracker.

Ben LinkApril 23, 2020NADAC, Medicaid, Generic, COVID, Naproxen, Hydroxychloroquine, Prograf, Tacrolimus, Naprosyn, Mytesi